118 related articles for article (PubMed ID: 3468564)
1. [Biotransformation of sparteine in the Cuna American Indians of Panama].
Arias TD; Jorge L; Lee D; Guerrero de Solís N; Escobar J; Barrantes R; Inaba T
Rev Med Panama; 1986 Sep; 11(3):199-209. PubMed ID: 3468564
[No Abstract] [Full Text] [Related]
2. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
3. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
Jorge LF; Arias TD
Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
[TBL] [Abstract][Full Text] [Related]
4. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
6. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
Ebner T; Meese CO; Eichelbaum M
Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
[TBL] [Abstract][Full Text] [Related]
8. [Population pharmacology and ethnopharmacokinetics in 3 Amerindian groups from Panama: Cuna, Ngawbe Guaymi and Teribe].
Arias TD; Jorge LF
Rev Med Panama; 1990 Jan; 15(1):20-6. PubMed ID: 2330419
[TBL] [Abstract][Full Text] [Related]
9. [Role of pharmacogenetics in psychopharmacotherapy].
Gram LF
Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
[TBL] [Abstract][Full Text] [Related]
10. The relationship between imipramine metabolism and the sparteine oxidation polymorphism.
Brøsen K
Dan Med Bull; 1988 Oct; 35(5):460-8. PubMed ID: 3066590
[No Abstract] [Full Text] [Related]
11. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
[TBL] [Abstract][Full Text] [Related]
12. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Nielsen F; Rosholm JU; Brøsen K
Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
14. [Heterologous expression of functionally active human cytochrome P-450. I. Synthesis of cytochrome P-450IID6 by transformed Saccharomyces cerevisiae cells].
Krynetskiĭ EIu; Kovaleva IE; El'darov MA; Luzikov VN
Mol Biol (Mosk); 1993; 27(5):1094-9. PubMed ID: 8246932
[TBL] [Abstract][Full Text] [Related]
15. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
16. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers.
Arias TD; Jorge LF; Lee D; Barrantes R; Inaba T
Clin Pharmacol Ther; 1988 Apr; 43(4):456-65. PubMed ID: 3356089
[TBL] [Abstract][Full Text] [Related]
17. A BamHI polymorphism in the human cytochrome P450 gene, CYP2D6.
Morimoto Y; Murayama N; Kuwano A; Yoshimura O; Kondo I
Clin Genet; 1995 Feb; 47(2):103-4. PubMed ID: 7606840
[No Abstract] [Full Text] [Related]
18. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
[TBL] [Abstract][Full Text] [Related]
20. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
